Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company, specializes in the emerging field of molecular medicine. The company is committed to applying innovations in the identification and targeting of disease to enhance patient healthcare by treating significant, but unmet medical needs. Their focus is on discovering, developing and commercializing novel radiotherapeutics and molecular imaging pharmaceuticals for initial application in the areas of oncology and cardiology. For further information, visit the Company’s web site at www.molecularinsight.com.
- 17 years ago
QualityStocks
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI)
Tags Rodman & Renshaw
Related Post
-
Perpetuals.com Ltd. (NASDAQ: PDC) Completes BayesShield(TM) AI Pilot, Reporting 92% Block Rate on Losing Retail Crypto Trades
The BayesShield AI system analyzed a full year of real retail trading data to validate…
-
QualityStocksNewsBreaks – SPACSphere Acquisition Corp. (NASDAQ: SSACU) Closes $172.5 Million Initial Public Offering
SPACSphere Acquisition (NASDAQ: SSACU) announced the closing of its initial public offering of 17,250,000 units…
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Featured by RADIO + TELEVISION BUSINESS REPORT for ADIO Engagement Platform and Real-Time Bias Meter
Datavault AI (NASDAQ: DVLT) is highlighted in the Winter 2026 issue (p. 27) of RADIO + TELEVISION BUSINESS REPORT, which examines…